PE20110147A1 - Composicion y proceso - 356 - Google Patents

Composicion y proceso - 356

Info

Publication number
PE20110147A1
PE20110147A1 PE2010001171A PE2010001171A PE20110147A1 PE 20110147 A1 PE20110147 A1 PE 20110147A1 PE 2010001171 A PE2010001171 A PE 2010001171A PE 2010001171 A PE2010001171 A PE 2010001171A PE 20110147 A1 PE20110147 A1 PE 20110147A1
Authority
PE
Peru
Prior art keywords
pyrimidin
salt
metoxybenzyl
metoxifenil
methylmorpholin
Prior art date
Application number
PE2010001171A
Other languages
English (en)
Inventor
Helen Blade
Gwydion Huw Churchill
Angela Charlotte Currie
Benjamin Charles Dobson
Peter Samuel Hynes
Martin Neal Kenworthy
Lyn Powel
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20110147A1 publication Critical patent/PE20110147A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL Y SUS SALES FOSFATO, SULFATO, MALATO, ENTRE OTROS; QUE COMPRENDE: A) REACCION DE UNA SAL DE 5-[(2E)-3-(DIMETILAMINO)PROP-2-ENOIL]-2-METOXIBENCILO DEL ACIDO PIVALICO O ESTER METILICO CON UN URACILO SUSTITUIDO EN LA POSICION 6 PARA OBTENER UNA SAL DE 5- (2,4-DIOXO-1,2,3,4-TETRAHIDROPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; B) REACCION DEL OBTENIDO CON UN AGENTE HALOGENANTE PARA OBTENER UNA SAL DE 5-(2,4-DIHALOPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; C) HACER REACCIONAR EL OBTENIDO CON METILMORFOLINA; D) ELIMINAR LOS GRUPOS PROTECTORES PARA OBTENER EL COMPUESTO (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL. ADICIONALMENTE SE PUEDE AISLAR EL COMPUESTO EN MENCION COMO UNA SAL. TAMBIEN REFIERE A UNA FORMULACION FARMACEUTICA. DICHO PROCESO ES UTIL PARA PREPARAR COMPUESTOS INHIBIDORES DE LA QUINASA mTOR UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA COMO EL CANCER
PE2010001171A 2008-06-20 2009-06-18 Composicion y proceso - 356 PE20110147A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
PE20110147A1 true PE20110147A1 (es) 2011-03-26

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001171A PE20110147A1 (es) 2008-06-20 2009-06-18 Composicion y proceso - 356

Country Status (27)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
HK (1) HK1155160A1 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
ES2259425T3 (es) 1999-09-07 2006-10-01 Syngenta Participations Ag Nuevos herbicidas.
CA2407593C (en) 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
JP2006525357A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー プロテインチロシンホスファターゼ阻害物質としての置換ヘテロアリール類
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
PL1954699T3 (pl) * 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
MY148688A (en) 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2009050506A2 (en) * 2007-10-15 2009-04-23 Astrazeneca Ab Combination 059

Also Published As

Publication number Publication date
DOP2010000391A (es) 2011-01-15
EA201100063A1 (ru) 2011-10-31
NI201000225A (es) 2011-12-15
ECSP10010696A (es) 2011-01-31
HK1155160A1 (en) 2012-05-11
EA019092B1 (ru) 2014-01-30
ES2398423T3 (es) 2013-03-19
BRPI0914912A2 (pt) 2017-06-20
MY172107A (en) 2019-11-14
UY31917A (es) 2010-01-29
MX2010014230A (es) 2011-03-29
EP2303875A2 (en) 2011-04-06
CA2728183A1 (en) 2009-12-23
SV2010003770A (es) 2011-05-20
US8198441B2 (en) 2012-06-12
CO6351729A2 (es) 2011-12-20
CN102137860A (zh) 2011-07-27
WO2009153597A2 (en) 2009-12-23
TW201012818A (en) 2010-04-01
IL210074A0 (en) 2011-02-28
CL2010001488A1 (es) 2011-07-15
JP5607614B2 (ja) 2014-10-15
WO2009153597A3 (en) 2010-05-06
US20090318434A1 (en) 2009-12-24
JP2011524889A (ja) 2011-09-08
AR072263A1 (es) 2010-08-18
ZA201101861B (en) 2011-11-30
IL210074A (en) 2015-07-30
CA2728183C (en) 2016-10-25
TWI441821B (zh) 2014-06-21
AU2009261688A1 (en) 2009-12-23
EP2303875B1 (en) 2012-11-28
CR11859A (es) 2011-02-25
KR101668497B1 (ko) 2016-10-21
CN102137860B (zh) 2013-08-28
AU2009261688B2 (en) 2012-07-05
KR20110027789A (ko) 2011-03-16

Similar Documents

Publication Publication Date Title
PE20110147A1 (es) Composicion y proceso - 356
AU2014272774B2 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
IL278766B1 (en) Molecule, n-(3-chloro-1 (pyridin-3-yl)-h 1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide for use in pest control
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
PE20100267A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
NZ605627A (en) Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
TN2009000084A1 (en) Adenosine derivatives as a2a receptor agonists
GB0607954D0 (en) Organic compounds
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
BR122012012032B1 (pt) usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas
EA201100969A1 (ru) Солевые формы органического соединения
NZ590179A (en) Fatty acid acetylated salicylates, diflunisal or triflusal and their uses
MA37405A1 (fr) Composés hétérocyclyle
PE20160874A1 (es) Compuestos quimicos
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
BR112014030577B1 (pt) Dihidronaftiridinas e compostos relacionados, bem como composições farmacêuticas compreendendo os mesmos
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
NZ714558A (en) Formulation comprising a hypolipidemic agent
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
CL2008003181A1 (es) Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal